Literature DB >> 14990611

Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature.

H-W Bernd1, K Sotlar, J Lorenzen, R Osieka, U Fabry, P Valent, H-P Horny.   

Abstract

Approximately 20% of patients with systemic mastocytosis (SM) have an associated haematological, clonal, non-mast cell lineage disease, and most exhibit an associated myelogenous neoplasm. This report describes a 48 year old man with acute myeloid leukaemia (AML) and a type t(8;21) cytogenetic abnormality. Associated bone marrow mastocytosis (a defined subtype of SM) was only detected after successful polychemotherapy in the state of bone marrow aplasia, and persisted after complete remission of AML. The diagnosis of mastocytosis was based on the demonstration of a multifocal dense mastocytic infiltrate. The atypical mast cells showed prominent spindling and an aberrant immunophenotype, with coexpression of tryptase, chymase, KIT, and CD25-which is expressed only on neoplastic (not normal) mast cells. In addition, the transforming somatic mutation D816V of the c-kit gene was detected. Re-examination of the pretherapeutic (initial) bone marrow revealed a slight diffuse increase in partially spindle shaped mast cells also exhibiting an abnormal immunophenotype, with CD25 expression, although compact mastocytic infiltrates were not detected. Because the D816V mutation was detected in the initial bone marrow specimen, strict application of three minor diagnostic criteria (spindling, CD25, D816V) enabled a diagnosis of SM-AML to be confirmed retrospectively in the initial bone marrow tissue.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14990611      PMCID: PMC1770248          DOI: 10.1136/jcp.2003.012864

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  18 in total

1.  One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes.

Authors:  Karl Sotlar; Luis Escribano; Olfert Landt; Stefanie Möhrle; Sonia Herrero; Antonio Torrelo; Ulrich Lass; Hans-Peter Horny; Burkhard Bültmann
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

Review 2.  Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis.

Authors:  Wolfgang R Sperr; Hans-Peter Horny; Peter Valent
Journal:  Int Arch Allergy Immunol       Date:  2002-02       Impact factor: 2.749

3.  Bone marrow findings in systemic mastocytosis.

Authors:  H P Horny; M R Parwaresch; K Lennert
Journal:  Hum Pathol       Date:  1985-08       Impact factor: 3.466

4.  Generalized cutaneous mastocytosis and acute myelogenous leukemia.

Authors:  D W Shaw; W Hocking; A R Ahmed
Journal:  Int J Dermatol       Date:  1983-03       Impact factor: 2.736

5.  Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.

Authors:  Vinod A Pullarkat; Carlos Bueso-Ramos; Raymond Lai; Steven Kroft; Carla S Wilson; Sheeja T Pullarkat; Xiangdong Bu; Maung Thein; M Lee; Russell K Brynes
Journal:  Am J Hematol       Date:  2003-05       Impact factor: 10.047

6.  Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His.

Authors:  V A Pullarkat; S T Pullarkat; D C Calverley; R K Brynes
Journal:  Am J Hematol       Date:  2000-12       Impact factor: 10.047

7.  Hematologic malignancies occurring in patients with urticaria pigmentosa.

Authors:  A J Cooper; R K Winkelmann; J C Wiltsie
Journal:  J Am Acad Dermatol       Date:  1982-08       Impact factor: 11.527

8.  Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val.

Authors:  W R Sperr; S Walchshofer; H P Horny; M Födinger; I Simonitsch; R Fritsche-Polanz; I Schwarzinger; E Tschachler; C Sillaber; W Hagen; K Geissler; A Chott; K Lechner; P Valent
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

9.  Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation.

Authors:  T-Y Chen; J-S Chen; W-T Huang; W-C Su; C-J Tsao
Journal:  Bone Marrow Transplant       Date:  2003-07       Impact factor: 5.483

10.  Significance of systemic mast cell disease with associated hematologic disorders.

Authors:  W D Travis; C Y Li; L T Yam; E J Bergstralh; R G Swee
Journal:  Cancer       Date:  1988-09-01       Impact factor: 6.860

View more
  14 in total

1.  "Occult" mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis.

Authors:  K Sotlar; W Saeger; F Stellmacher; J Stahmer; S Jäckle; P Valent; H-P Horny
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

2.  High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.

Authors:  Robert Fritsche-Polanz; Marika Fritz; Andrea Huber; Karl Sotlar; Wolfgang R Sperr; Christine Mannhalter; Manuela Födinger; Peter Valent
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

Review 3.  Pediatric Mastocytosis: A Review of the Literature.

Authors:  Marianne Frieri; Mahvish Quershi
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2013-12-01       Impact factor: 1.349

4.  International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.

Authors:  Jason Gotlib; Animesh Pardanani; Cem Akin; Andreas Reiter; Tracy George; Olivier Hermine; Hanneke Kluin-Nelemans; Karin Hartmann; Wolfgang R Sperr; Knut Brockow; Lawrence B Schwartz; Alberto Orfao; Daniel J Deangelo; Michel Arock; Karl Sotlar; Hans-Peter Horny; Dean D Metcalfe; Luis Escribano; Srdan Verstovsek; Ayalew Tefferi; Peter Valent
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

5.  Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia.

Authors:  Sheeja T Pullarkat; Vinod Pullarkat; Steven H Kroft; Carla S Wilson; Arshad N Ahsanuddin; Karen P Mann; Maung Thein; Wayne W Grody; Russell K Brynes
Journal:  J Hematop       Date:  2009-02-10       Impact factor: 0.196

6.  Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.

Authors:  Sa A Wang; Lloyd Hutchinson; Guilin Tang; Su S Chen; Patricia M Miron; Yang O Huh; Dan M Jones; Carlos Bueso-Ramos; Srdan Verstovsek; L Jeffrey Medeiros; Roberto N Miranda
Journal:  Am J Hematol       Date:  2013-03       Impact factor: 10.047

7.  A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Mi Hyun Bae; Hyun-Ki Kim; Chan-Jeoung Park; Eul-Ju Seo; Sang Hyuk Park; Young-Uk Cho; Seongsoo Jang; Hyun-Sook Chi; Kyu-Hyung Lee
Journal:  Ann Lab Med       Date:  2013-02-21       Impact factor: 3.464

8.  Systemic mastocytosis with acute myelomonocytic leukemia: a case report.

Authors:  Rakhee Kar; Seema Rao; Hara Prasad Pati
Journal:  Indian J Hematol Blood Transfus       Date:  2009-01-11       Impact factor: 0.900

9.  [Mastocytosis and eosinophilic leukemia: diagnostics and classification].

Authors:  K Sotlar; P Valent; H-P Horny
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

10.  Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis.

Authors:  Jeffrey W Craig; Robert P Hasserjian; Annette S Kim; Jon C Aster; Geraldine S Pinkus; Jason L Hornick; David P Steensma; R Coleman Lindsley; Daniel J DeAngelo; Elizabeth A Morgan
Journal:  Mod Pathol       Date:  2020-01-02       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.